Epitalon

What people use it for

• Longevity and anti-aging (the telomere claim)S1S2S3
• Sleep and circadian rhythmS1S2S3

Reported regimens

Reported side effects

• injection-site redness, swelling or irritationS2S3
• drowsiness or mild fatigueS2S3
• mild headacheS2

Reported benefits (claims, not shown in trials)

• better sleep during the courseS1
• more energy and well-being, described as subtleS1

Cautions

• Nearly all published epitalon research comes from one research group (Khavinson, St. Petersburg). Few independent labs have repeated it.S1S2
• Cell studies show telomerase activation, but this may not mean longer telomeres in people after a short course. S2 notes one cell study saw telomere lengthening in cancer cell lines too, and calls the cancer concern theoretical.S1S2
• S3 says to avoid epitalon in pregnancy, breastfeeding, under age 18, active cancer or a strong cancer history without clinician oversight. S3 also says the FDA flags compounding safety-risk concerns for epitalon.S3
• Product from research-chemical suppliers has risks of contamination, wrong dose and unknown impurities.S2
• S2 reports that doses above 10 mg a day are used by some people, and that no published data shows they work better.S2

Status notes

• As of 2026-10-30, HHS's draft policy says it does not plan to act against licensed pharmacies or physicians that make epitalon acetate for a patient with a prescription, under strict conditions. It gives no legal rights and does not bind HHS or the public. It does not grant FDA approval or add the substance to the 503A bulks list, the list of ingredients allowed for this compounding. The listed routes are injection under the skin (subcutaneous) or into a muscle (intramuscular). The compounder must dispense it in intermittent courses, with breaks between courses.S6S7
• Only a licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician, can compound under this policy. They need a valid prescription for the individual patient. The original manufacturer must register with FDA under section 510 and meet current good manufacturing practice (CGMP) standards and other applicable federal drug requirements. A valid certificate of analysis, the batch's test report, must identify the manufacturing site and meet Appendix B's testing standards. The ingredient must match Appendix B's identity, including its amino acid sequence, chemical structure, molecular weight, and molecular formula. Tests must cover identity, purity, potency, and harmful contaminants, including endotoxins, heavy metals, microbes, and impurities. If an FDA-registered repacker, relabeler, or reseller supplies it, that business must document checks of the original manufacturer and its certificate. The product must contain only one active ingredient from Appendix A.S6
• Compounders must report products, serious adverse events, and product quality problems to FDA and the states where they make and send the products. Each product report must give the active ingredient, its strength per unit, the original manufacturer, and the manufacturing facility's unique identifier. It must also give the dosage form and route. Compounders must report serious adverse events to FDA MedWatch even if they do not consider the drug responsible. The patient's label must explain how to report adverse events and problems with identity, strength, purity, or quality. It must state: "This is a compounded drug product. Not for resale."S6
• Any device packaged with the drug, or containing it, must be an FDA 510(k)-cleared syringe. All other applicable federal drug requirements still apply, including sanitary conditions.S6
• This 503A policy does not cover 503B outsourcing facilities, research chemicals, supplements, or blends. It applies only until a final rule includes or excludes the substance from the 503A bulks list. HHS may reconsider the policy, including if safety or product quality problems arise.S6
• Federal Register document 2026-22192 was filed on 2026-10-28 and published on 2026-10-30. Docket: HHS-OASH-2026-0496. The notice allows comments for two weeks after publication. That gives a comment date of 2026-11-13.S7
• The FDA Pharmacy Compounding Advisory Committee met on 2026-07-23 and 2026-07-24. It recommended adding epitalon to the 503A bulks list. This is a recommendation, not an FDA decision.S4S5
• Epitalon is not FDA-approved for any use. S2 reports it is sold as a research chemical.S2

Community sources

• S1Epitalon: Community Protocols & Reportspeptideprotocolwiki.comcarries seller links, not linked
• S2Epithalon: Telomerase-Activating Peptide for Longevitypeptidepedia.orgcarries seller links, not linked
• S3Epitalon: Benefits, Dosage & Side Effectsoutliyr.comcarries seller links, not linked
• S4FDA's Advisory Committee Votes on Peptides: What It Does and Doesn't Do (opens in a new tab)mintz.com
• S5From mice to gym rats: unregulated use of peptides (Los Angeles Times) (opens in a new tab)newstribune.com
• S6HHS interim 503A peptide enforcement policy, Appendix B (opens in a new tab)hhs.gov
• S7Federal Register 2026-22192, published 2026-10-30 (opens in a new tab)federalregister.gov